PROQR THERAPEUTICS Financials
| 0PQ Stock | EUR 3.40 0.01 0.29% |
PROQR |
Understanding current and past PROQR THERAPEUTICS Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of PROQR THERAPEUTICS's financial statements are interrelated, with each one affecting the others. For example, an increase in PROQR THERAPEUTICS's assets may result in an increase in income on the income statement.
PROQR THERAPEUTICS Stock Summary
PROQR THERAPEUTICS competes with MACOM Technology, SCOTT TECHNOLOGY, Park Hotels, MELIA HOTELS, and Sunny Optical. ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands. PROQR THERAPEUTICS is traded on Frankfurt Stock Exchange in Germany.| Instrument | Germany Stock View All |
| Exchange | Frankfurt Exchange |
| ISIN | NL0010872495 |
| Business Address | Zernikedreef 9 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.proqr.com |
| Phone | 31 88 166 7000 |
| Currency | EUR - Euro |
You should never invest in PROQR THERAPEUTICS without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of PROQR Stock, because this is throwing your money away. Analyzing the key information contained in PROQR THERAPEUTICS's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
PROQR THERAPEUTICS Key Financial Ratios
There are many critical financial ratios that PROQR THERAPEUTICS's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that PROQR THERAPEUTICS reports annually and quarterly.| Return On Equity | -0.75 | |||
| Return On Asset | -0.26 | |||
| Target Price | 24.96 | |||
| Number Of Employees | 181 | |||
| Beta | 0.22 |
PROQR Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining PROQR THERAPEUTICS's current stock value. Our valuation model uses many indicators to compare PROQR THERAPEUTICS value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across PROQR THERAPEUTICS competition to find correlations between indicators driving PROQR THERAPEUTICS's intrinsic value. More Info.PROQR THERAPEUTICS EO 04 is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the PROQR THERAPEUTICS's earnings, one of the primary drivers of an investment's value.PROQR THERAPEUTICS Systematic Risk
PROQR THERAPEUTICS's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. PROQR THERAPEUTICS volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on PROQR THERAPEUTICS correlated with the market. If Beta is less than 0 PROQR THERAPEUTICS generally moves in the opposite direction as compared to the market. If PROQR THERAPEUTICS Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one PROQR THERAPEUTICS is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of PROQR THERAPEUTICS is generally in the same direction as the market. If Beta > 1 PROQR THERAPEUTICS moves generally in the same direction as, but more than the movement of the benchmark.
PROQR THERAPEUTICS December 2, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of PROQR THERAPEUTICS help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of PROQR THERAPEUTICS EO 04. We use our internally-developed statistical techniques to arrive at the intrinsic value of PROQR THERAPEUTICS EO 04 based on widely used predictive technical indicators. In general, we focus on analyzing PROQR Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build PROQR THERAPEUTICS's daily price indicators and compare them against related drivers.
| Downside Deviation | 3.86 | |||
| Information Ratio | 0.1007 | |||
| Maximum Drawdown | 138.31 | |||
| Value At Risk | (5.62) | |||
| Potential Upside | 7.1 |
Complementary Tools for PROQR Stock analysis
When running PROQR THERAPEUTICS's price analysis, check to measure PROQR THERAPEUTICS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PROQR THERAPEUTICS is operating at the current time. Most of PROQR THERAPEUTICS's value examination focuses on studying past and present price action to predict the probability of PROQR THERAPEUTICS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PROQR THERAPEUTICS's price. Additionally, you may evaluate how the addition of PROQR THERAPEUTICS to your portfolios can decrease your overall portfolio volatility.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |